The dvm360® oncology page is a comprehensive resource for clinical news and insights on the latest in veterinary oncology. This page consists of videos, interviews, articles, podcasts, and research on the advancements and developments of therapies for oncology, and more.
November 12th 2024
Canalevia-CA1 is currently the only treatment on the market for treating CID in canine patients.
September 24th 2024
Update on canine hemangiosarcoma (Proceedings)
May 1st 2011Canine hemangiosarcoma (HSA), a malignant tumor of blood vessel endothelial cells, is a relatively common malignancy in dogs compared with other species. In fact, owing to its rareness in humans, we do not have abundant human literature from which to extrapolate when making treatment decisions. Certain breeds (e.g. German shepherds, golden retrievers) appear to be at increased risk for the development of HSA, suggesting a possible genetic predisposition.
What's new in canine osteosarcoma – the CSU experience (Proceedings)
May 1st 2011Osteosarcoma (OSA) represents the most common bony tumor of dogs and cats. Although information regarding etiopathogenesis is lacking, OSA of the long bones (appendicular OSA) is far more common in large and giant breed dogs than in smaller dogs. Rare causes of OSA include those associated with metallic implants, those formed after radiation therapy, and some feline vaccine-associated sarcomas.
Dispelling the myths of veterinary cancer and its treatment (Proceedings)
May 1st 2011Often, the primary clinician may be the veterinarian making a diagnosis of cancer in a pet and performing the initial client education regarding their pet's disease. Critically important, life-or death decisions regarding euthanasia, treatment, choice to pursue referral, etc. may be made based on information that the owner gets from their primary veterinarian.
Case studies in behavioral pharmacological therapy (Proceedings)
May 1st 2011Our knowledge of the brain on the neurochemical, genetic and molecular level is increasing steadily each year. Despite this, little is definitively known about the neurochemical correlates of various disease processes. Much of our knowledge concerning the etiology of mental illness comes from response to pharmacological intervention.
Hot Literature: Long-term success for masitinib in dogs with MCTs
January 3rd 2011Investigators from the University of Tennessee's College of Veterinary Medicine recently published their findings evaluating tumor response and overall survival rate and time for dogs with nonresectable MCTs treated with masitinib.
Missouri to test human cancer drug for canine use
December 10th 2010Columbia, Mo. -- Researchers at the University of Missouri (MU) College of Veterinary Medicine have started a clinical trial on a human oncology drug which may prove useful in the battle against canine cancer. The drug Attaxol?, which is made by CritiTech in Lawrence, Kan., could be ideal for use in dogs with naturally occurring cancer, says Dr. Kim Seltin, assistant professor of oncology at the MU College of Veterinary Medicine.
Getting the most from the histopathology (Proceedings)
November 1st 2010Biopsy and histopathology remains the gold standard diagnostic test for many conditions and for nearly all tumors and cancers. When performing this test, it is important to know what answers to look for, in order to obtain as much critical information as possible that may eventually impact the prognosis and the treatment planning.